Microbiome and mycobiome cross-talk from an immunobiotic perspective in COVID-19 and post-acute COVID-19 syndrome

Abstract

Coronavirus disease 2019 (COVID-19) infected individuals showed either mild symptoms or were paucisymptomatic, with severe impact on human health, revealing heightened risk and direct effects on health. Among various factors contributing to complications, bacterial and fungal co-infection remains very common and is highly lethal. This narrative review aims to focus on the collective role of gut microbiota and mycobiota in COVID-19. Fungal infection has been identified as a key risk factor for the spread of COVID-19 and mortality. Gut mycobiomes diversity and abundance also vary due to the different types of SARS-CoV-2 variant infection. Their cross-talk plays a vital role in immune regulation and disease severity, with an emphasis on understanding the altered condition as a predictive marker. On the other hand, the gut microbiome is well known for shaping metabolic functions, generating immune responses, and deciphering the signal to decide the healthy state and disease condition of an individual. Immune response during COVID-19 infection was also linked with metabolites produced by the gut microflora, specifically amino acids, sugar metabolites, and neurotransmitters. The cross-talk between gut microbiota and gut mycobiota for clinical implications in terms of early detection, identification of the disease severity, and even therapeutic alternatives will open newer avenues. A deep dive understanding of the cross-talk between the microbiome and mycobiome, and their role in immune response will take scientific discovery knowledge to develop gut-targeted safe therapeutic approaches in the form of FMT (fecal microbiota transplantation) probiotics, peptides, antibacterial, and antifungal metabolites. Overall cross-talk and immune interplay are critical determinants of host immunity, providing insights into their role and key take home lessons for better management of crisis in the future.

Keywords

Gut mycobiota / gut microbiota / COVID-19 / inflammation / immune response / PACS

References

[1] Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022; 23: 3-20.

[2] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020; 80: 607-13.

[3] Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G, et al. Evolution patterns of SARS-CoV-2: Snapshot on its genome variants. Biochem Biophys Res Commun. 2021; 538: 88-91.

[4] Aleem A, Akbar Samad AB, Vaqar S. Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19). Treasure Island (FL): StatPearls Publishing; 2025.

[5] Liu J, Yang D, Wang X, Asare PT, Zhang Q, Na L, et al. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol. 2022; 12: 774335.

[6] Negi S, Das DK, Pahari S, Nadeem S, Agrewala JN. Potential Role of Gut Microbiota in Induction and Regulation of Innate Immune Memory. Front Immunol. 2019; 10: 2441.

[7] Rowan-Nash AD, Korry BJ, Mylonakis E, Belenky P. Cross-Domain and Viral Interactions in the Microbiome. Microbiol Mol Biol Rev. 2019; 83: e00044-18.

[8] Houghteling PD, Walker WA. Why is initial bacterial colonization of the intestine important to infants’ and children’s health? J Pediatr Gastroenterol Nutr. 2015; 60: 294-307.

[9] Bull MJ, Plummer NT. Part 1: The Human Gut Microbiome in Health and Disease. Integr Med (Encinitas). 2014; 13: 17-22.

[10] Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients. 2012; 4: 1095-119.

[11] Prajapati B, Jena PK, Rajput P, Purandhar K, Seshadri S. Understanding and modulating the Toll like Receptors (TLRs) and NOD like Receptors (NLRs) cross talk in type 2 diabetes. Curr Diabetes Rev. 2014; 10: 190-200.

[12] Wirusanti NI, Baldridge MT, Harris VC. Microbiota regulation of viral infections through interferon signaling. Trends Microbiol. 2022; 30: 778-92.

[13] Yang J, Yang H, Li Y. The triple interactions between gut microbiota, mycobiota and host immunity. Crit Rev Food Sci Nutr. 2023; 63: 11604-24.

[14] Singh K, Rao A. Probiotics: A potential immunomodulator in COVID-19 infection management. Nutr Res. 2021; 87: 1-12.

[15] Nagata N, Takeuchi T, Masuoka H, Aoki R, Ishikane M, Iwamoto N, et al. Human Gut Microbiota and Its Metabolites Impact Immune Responses in COVID-19 and Its Complications. Gastroenterology. 2023; 164: 272-88.

[16] Ng SC, Peng Y, Zhang L, Mok CK, Zhao S, Li A, et al. Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events. Gut. 2022; 71: 1106-16.

[17] Alexander JL, Mullish BH, Danckert NP, Liu Z, Olbei ML, Saifuddin A, et al. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients. EBioMedicine. 2023; 88: 104430.

[18] Hong S. Influence of Microbiota on Vaccine Effectiveness: “Is the Microbiota the Key to Vaccine-induced Responses?”. J Microbiol. 2023; 61: 483-94.

[19] Hong M, Lan T, Li Q, Li B, Yuan Y, Xu F, et al. A comprehensive perspective on the interaction between gut microbiota and COVID-19 vaccines. Gut Microbes. 2023; 15: 2233146.

[20] Huffnagle GB, Noverr MC. The emerging world of the fungal microbiome. Trends Microbiol. 2013; 21: 334-41.

[21] Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016; 16: 341-52.

[22] Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022; 7: 1127-40.

[23] Yokoyama Y, Ichiki T, Yamakawa T, Tsuji Y, Kuronuma K, Takahashi S, et al. Gut microbiota and metabolites in patients with COVID-19 are altered by the type of SARS-CoV-2 variant. Front Microbiol. 2024; 15: 1358530.

[24] Linnakoski R, Reshamwala D, Veteli P, Cortina-Escribano M, Vanhanen H, Marjomäki V. Antiviral Agents From Fungi: Diversity, Mechanisms and Potential Applications. Front Microbiol. 2018; 9: 2325.

[25] Song G, Liang G, Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia. 2020; 185: 599-606.

[26] Maeda Y, Motooka D, Kawasaki T, Oki H, Noda Y, Adachi Y, et al. Longitudinal alterations of the gut mycobiota and microbiota on COVID-19 severity. BMC Infect Dis. 2022; 22: 572.

[27] Mahalaxmi I, Jayaramayya K, Venkatesan D, Subramaniam MD, Renu K, Vijayakumar P, et al. Mucormycosis: An opportunistic pathogen during COVID-19. Environ Res. 2021; 201: 111643.

[28] Parolin C, Marangoni A, Laghi L, Foschi C, Ñahui Palomino RA, Calonghi N, et al. Isolation of Vaginal Lactobacilli and Characterization of Anti-Candida Activity. PLoS One. 2015; 10: e0131220.

[29] Altıntaş M, Kar M, Tığlı GA, Çekin YJA. Methicillin Resistance and Staphylococcus aureus in Nasal Cultures Before and During the Covid-19 Pandemic: A Comparison of the Results. Eur J Rhinol Allergy. 2022; 5: 20-3.

[30] Rizzetto L, Ifrim DC, Moretti S, Tocci N, Cheng S, Quintin J, et al. Fungal Chitin Induces Trained Immunity in Human Monocytes during Cross-talk of the Host with Saccharomyces cerevisiae . J Biol Chem. 2016; 291: 7961-72.

[31] Bulgasem BY, Lani MN, Hassan Z, Wan Yusoff WM, Fnaish SG. Antifungal Activity of Lactic Acid Bacteria Strains Isolated from Natural Honey against Pathogenic Candida Species. Mycobiology. 2016; 44: 302-9.

[32] Li XV, Leonardi I, Iliev ID. Gut Mycobiota in Immunity and Inflammatory Disease. Immunity. 2019; 50: 1365-79.

[33] Wang B, Zhang L, Wang Y, Dai T, Qin Z, Zhou F, et al. Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2022; 7: 143.

[34] Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 2015; 11: 577-91.

[35] Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013; 504: 451-5.

[36] Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009; 461: 1282-6.

[37] Karst SM. The influence of commensal bacteria on infection with enteric viruses. Nat Rev Microbiol. 2016; 14: 197-204.

[38] Johnson BA, Hage A, Kalveram B, Mears M, Plante JA, Rodriguez SE, et al. Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity. J Virol. 2019; 93: e01282-19.

[39] Mustafa S, Balkhy H, Gabere MN. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review. J Infect Public Health. 2018; 11: 9-17.

[40] Chao YX, Rötzschke O, Tan E. The role of IgA in COVID-19. Brain Behav Immun. 2020; 87: 182-3.

[41] Schaefer AK, Melnyk JE, He Z, Del Rosario F, Grimes CL. Pathogen-and microbial-associated molecular patterns (PAMPs/MAMPs) and the innate immune response in Crohn’s disease. Immunity and Inflammation in Health and Disease. Academic Press; 2018. pp. 175-87.

[42] Du L, He Y, Zhou Y, Liu S, Zheng B, Jiang S. The spike protein of SARS-CoV - a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009; 7: 226-36.

[43] Gorbach SL. Microbiology of the Gastrointestinal Tract. In: Baron S, editor. Medical Microbiology. 4th ed. Galveston (TX): University of Texas Medical Branch at Galveston; 1996.

[44] Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol. 2021; 69: 1002-4.

[45] Yusuf E, Seghers L, Hoek RAS, van den Akker JPC, Bode LGM, Rijnders BJA. Aspergillus in Critically Ill COVID-19 Patients: A Scoping Review . J Clin Med. 2021; 10: 2469.

[46] Moreno-Corona NC, López-Ortega O, Pérez-Martínez CA, Martínez-Castillo M, De Jesús-González LA, León-Reyes G, et al. Dynamics of the Microbiota and Its Relationship with Post-COVID-19 Syndrome. Int J Mol Sci. 2023; 24: 14822.

[47] Chiappelli F, Fotovat L. Post acute CoViD-19 syndrome (PACS) - Long CoViD. Bioinformation. 2022; 18: 908-11.

[48] Krasaewes K, Chaiwarith R, Chattipakorn N, Chattipakorn SC. Profiles of gut microbiota associated with clinical outcomes in patients with different stages of SARS-CoV-2 infection. Life Sci. 2023; 332: 122136.

[49] Zhang F, Lau RI, Liu Q, Su Q, Chan FKL, Ng SC. Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications. Nat Rev Gastroenterol Hepatol. 2023; 20: 323-37.

[50] Zhang X, Song X, Hu X, Chen F, Ma C. Health benefits of proanthocyanidins linking with gastrointestinal modulation: An updated review. Food Chem. 2023; 404: 134596.

[51] Coccia M. Improving preparedness for next pandemics: Max level of COVID-19 vaccinations without social impositions to design effective health policy and avoid flawed democracies. Environ Res. 2022; 213: 113566.

[52] Farmani AR, Swanson RJ, Mahdavinezhad F, Shoormeij MH, Mohammadi S, Moeinzadeh A, et al. Potential Application of Picosecond Pulsed Electric Field (PPEF): Advanced Bioelectrical Technology for Potential COVID-19 Treatment. New Mater Electrochem Syst. 2021; 24: 293-6.

[53] Farmani AR, Mahdavinezhad F, Scagnolari C, Kouhestani M, Mohammadi S, Ai J, et al. An overview on tumor treating fields (TTFields) technology as a new potential subsidiary biophysical treatment for COVID-19. Drug Deliv Transl Res. 2022; 12: 1605-15.

[54] Kitsios GD, Sayed K, Fitch A, Yang H, Britton N, Shah F, et al. Longitudinal multicompartment characterization of host-microbiota interactions in patients with acute respiratory failure. Nat Commun. 2024; 15: 4708.

[55] Shankar J. Food Habit Associated Mycobiota Composition and Their Impact on Human Health. Front Nutr. 2021; 8: 773577.

[56] Coccia M. COVID-19 vaccination is not a sufficient public policy to face crisis management of next pandemic threats. Public Organiz Rev. 2023; 23: 1353-67.